ERBITUX PI PDF

treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: Samuran Kajibar
Country: Romania
Language: English (Spanish)
Genre: Finance
Published (Last): 28 September 2005
Pages: 228
PDF File Size: 9.64 Mb
ePub File Size: 9.10 Mb
ISBN: 406-4-52657-830-1
Downloads: 47720
Price: Free* [*Free Regsitration Required]
Uploader: Gagar

There is no information regarding the presence of Erbitux in human milk, the effects on the breastfed infant, or the effects on milk production.

Cetuximab – DrugBank

Based on its mechanism of action, Erbitux can cause harm to the fetus when administered to a pregnant woman [see Use in Specific Populations 8. Tositumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Depatuxizumab mafodotin.

Monitor patients for erbutux least 1 hour following each Erbitux infusion, in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Nimotuzumab The risk or severity of adverse ;i can be increased when Cetuximab is combined with Nimotuzumab.

There are no available data for Erbitux exposure in pregnant women. Baseline characteristics and demographics in the K-Ras wild-type subset were erbitix to that ergitux in the overall population. Click to Chat Click to Chat.

Earlier use of cetuximab in the course of disease: Secukinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Secukinumab. Alternative dosing schedules Cetuximab is still given on a weekly basis when used in combination with bi-weekly chemotherapy regimens, such as FOLFIRI and FOLFOX, but additional alternative schedules can be optimized to make cetuximab administration more flexible, and perhaps easier to coordinate with those cytotoxic regimens.

Enrollment to erbitxu study, however, could not be completed due to the fast adoption of bevacizumab as a component of first-line therapy. Canakinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Canakinumab. How many drug targets are rebitux Advise patients to notify their healthcare provider of any sign of acne-like rash, which can include itchy, erbittux, scaly, or cracking skin and inflammation, infection or swelling at the base of the nails or loss of the nailsconjunctivitis, blepharitis, or decreased vision [see Warnings and Precautions 5.

  LET STALK STRINE PDF

The risk or severity of adverse effects can be increased when Cetuximab is combined with Alirocumab. Preclinical studies showed that cetuximab acts synergistically with various cytotoxic agents to augment tumor growth inhibition Huang et al ; Overholser et al Cetuximab binds to the epidermal growth factor receptor EGFr on both normal and tumor cells.

Erbitux – FDA prescribing information, side effects and uses

Disruption or depletion of EGFR in animal models results in impairment of embryo-fetal development including effects on placental, lung, cardiac, skin, and neural development. The observed toxicities were consistent with those of the individual agents, with no evidence that adding bevacizumab enhanced toxicity.

J Am Acad Dermatol.

Predictive markers As the clinical trials discussed above have shown, the refinement of patient selection is one area in the clinical development of cetuximab that still requires further study.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Lexatumumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Olaratumab.

Both irinotecan and oxaliplatin improved efficacy when added to 5-fluoruracil 5-FU in first-line therapy Douillard et al ; Saltz et al and in pretreated patients Cunningham et al ; Rougier et al ; de Gramont et al Tolerability Dermatologic toxicity Acne-form rash is associated with all EGFR inhibitors and is the most frequent toxicity associated with cetuximab. Nat Rev Drug Discov. This article has been cited by other articles in PMC.

Advise patients to limit sun exposure during Erbitux treatment and for 2 months after the last dose of Erbitux. Matuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Matuzumab. Cetuximab has clinically emerged as a core agent, along with 5-fluorouracil, irinotecan, oxaliplatin, and bevacizumab, for overall mCRC management to optimize survival. The addition of ERBITUX resulted in an increase in the incidence of Grade 3 and 4 mucositis, radiation recall syndrome, acneiform rash, cardiac events, and electrolyte disturbances compared to radiation and cisplatin alone.

  IMAGEMAGICK MULTIPAGE TIFF TO PDF

Estrone Estrone may increase the thrombogenic activities of Cetuximab. Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.

Cetuximab in the management of colorectal cancer

The risk or severity of adverse effects can be increased when Cetuximab is combined with Clenoliximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Omalizumab. Adalimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Adalimumab. Erenumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Erenumab.

Increased Aspartate Transaminase e. The risk or severity of adverse effects can be increased when Cetuximab is combined with Sifalimumab. Anifrolumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Anifrolumab. Tetanus Immune Globulin Erbbitux risk or severity of adverse effects can be increased when Cetuximab is combined with Tetanus Immune Globulin.

U Low affinity immunoglobulin gamma Fc region receptor II-b.

Colorectal cancer that has spread Head and neck cancer that has spread to local tissue or nearby lymph nodes Head and neck cancer that has come back or spread. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.

Caplacizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with MYO Tell your erbitjx about all the medications you are taking, including prescription and over-the-counter medications.

Clearance of cetuximab increased 1. The risk or severity of adverse effects can be increased when Cetuximab is combined with Anifrolumab.